Holen Sie sich die Stockscreener-App
2.06
0.49%
0.01
Handel nachbörslich:
2.02
-0.04
-1.94%
Schlusskurs vom Vortag:
$2.05
Offen:
$2.02
24-Stunden-Volumen:
12,344
Relative Volume:
0.05
Marktkapitalisierung:
$5.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.11M
KGV:
-0.1922
EPS:
-10.7181
Netto-Cashflow:
$-13.60M
1W Leistung:
+0.00%
1M Leistung:
-2.83%
6M Leistung:
-26.43%
1J Leistung:
-51.44%
1-Tages-Spanne:
$2.01
$2.0825
1-Wochen-Bereich:
$2.01
$2.18
52-Wochen-Spanne:
$1.6701
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Firmenname
Processa Pharmaceuticals Inc
Sektor
Branche
Telefon
443-776-3133
Adresse
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.06 | 5.99M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-25 | Eingeleitet | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Processa Pharmaceuticals Inc. (PCSA) Peer Comparison – Compare with Others - valueresearchonline.com
Processa Pharmaceuticals Inc. (PCSA) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Processa Pharmaceuticals Inc. (PCSA) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Processa Pharmaceuticals Inc. (PCSA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Processa (PCSA) Range: Closes 0.47% Lower at $2.14 in Latest Trading; Next Test: Support at $2.03 and Resistance at $2.25 Frame the RangeDark Pool Volume - vinanet.vn
Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control - Stock Titan
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsChaikin Flow - dars.gov.et
Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary - TradingView
Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition - Stock Titan
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com Nigeria
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) Slips 2.34% to $2.5 as Support at $2.38 Comes into FocusPercent Above MA - vinanet.vn
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com UK
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) Surges 11.74% to $2.57 — Poised for a Test of $2.70 ResistanceQuality Factor - vinanet.vn
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates - Kalkine
Processa Pharmaceuticals Inc (PCSA) Stock News Today - TradingKey
Processa Pharmaceuticals, Inc. 8-K SEC Filing Details – Nasdaq Listed Company Information (July 30, 2026) - Minichart
Processa Pharmaceuticals Shareholders Approve Key Governance Changes - TipRanks
Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares - Stock Titan
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - Mintz
Form 4 Processa Pharmaceuticals Inc For: 30 July By Investing.com - Investing.com Nigeria
Processa acquires Vidya and its BTK inhibitor - The Pharma Letter
Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors - marketscreener.com
Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License - TradingView
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA - GlobeNewswire
Processa Pharmaceuticals acquires Vidya, raises strategic funding - TipRanks
Processa Pharmaceuticals Inc - TradingKey
Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) grants director 33,500 RSUs and reports option stake - Stock Titan
Processa Pharmaceuticals (PCSA) awards 8,450 RSUs and reports option, stock holdings - Stock Titan
Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.080|Chg%:-0.065 - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005 - TradingKey
Processa Pharma Market Sentiment - Benzinga España
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Inc (PCSA) Income Statement - TradingKey
Processa Pharmaceuticals Inc (PCSA) Balance Sheet - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.050|Chg%:-0.050 - TradingKey
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PCSA Q4 2025 Earnings: Significant EPS Miss Highlights Ongoing Development CostsRevenue Growth Report - vinanet.vn
Processa Pharmaceuticals (PCSA) Shares Rise 3% as Support Holds Above $2.19Triple Bottom - vinanet.vn
PCSA Q4 2025 Earnings: Deeper Loss Per Share Yet Stock Rises 4.2% – Investor Focus Shifts to Pipeline ProgressTax Rate Impact - dars.gov.et
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates, No Revenue ReportedOperating Margin Analysis - dars.gov.et
Processa Pharmaceuticals Q4 2025 Earnings: EPS Miss Drives Stock Surge – Investor Focus Shifts to Pipeline - dars.gov.et
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights - Benzinga España
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock - Investing.com
Finanzdaten der Processa Pharmaceuticals Inc-Aktie (PCSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Processa Pharmaceuticals Inc-Aktie (PCSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lin Patrick | Chief Business - Strategy Off |
Jun 30 '26 |
Buy |
1.93 |
2,106 |
4,065 |
13,113 |
| Ng George K | Chief Executive Officer |
Jul 01 '26 |
Buy |
1.93 |
3,057 |
5,900 |
15,492 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 30 '26 |
Buy |
1.93 |
3,277 |
6,325 |
16,689 |
| Young David | Pres. Research & Development |
Jun 30 '26 |
Buy |
1.93 |
2,531 |
4,885 |
21,729 |
| Young David | Pres. Research & Development |
Jun 15 '26 |
Buy |
2.22 |
2,067 |
4,589 |
19,198 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| Young David | Pres. Research & Development |
May 29 '26 |
Buy |
2.57 |
1,786 |
4,590 |
17,131 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):